About Retrophin (NASDAQ:RTRX)
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase I clinical trial for the treatment of phenylketonuria; and Liquid Ursodeoxycholic Acid, a liquid formulation of ursodeoxycholic acid, which is in Phase III clinical trial for the treatment of primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RTRX
CUSIPN/A
Phone760-260-8600
Debt
Debt-to-Equity Ratio0.15
Current Ratio5.07
Quick Ratio4.98
Price-To-Earnings
Trailing P/E Ratio-19.02
Forward P/E Ratio-16.78
P/E GrowthN/A
Sales & Book Value
Annual Sales$154.94 million
Price / Sales7.34
Cash FlowN/A
Price / CashN/A
Book Value$7.46 per share
Price / Book3.82
Profitability
EPS (Most Recent Fiscal Year)($1.50)
Net Income$-59,730,000.00
Net Margins-41.95%
Return on Equity-20.27%
Return on Assets-11.80%
Miscellaneous
Employees173
Outstanding Shares39,860,000
Retrophin (NASDAQ:RTRX) Frequently Asked Questions
What is Retrophin's stock symbol?
Retrophin trades on the NASDAQ under the ticker symbol "RTRX."
How were Retrophin's earnings last quarter?
Retrophin Inc (NASDAQ:RTRX) released its earnings results on Tuesday, May, 1st. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.25. The biopharmaceutical company earned $38.43 million during the quarter, compared to analyst estimates of $39.32 million. Retrophin had a negative net margin of 41.95% and a negative return on equity of 20.27%. The business's revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.01 earnings per share. View Retrophin's Earnings History.
What price target have analysts set for RTRX?
1 equities research analysts have issued 1-year target prices for Retrophin's shares. Their forecasts range from $43.00 to $43.00. On average, they expect Retrophin's stock price to reach $43.00 in the next twelve months. View Analyst Ratings for Retrophin.
Who are some of Retrophin's key competitors?
Some companies that are related to Retrophin include HUTCHISON CHINA/S (HCM), Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Portola Pharmaceuticals (PTLA) and Emergent Biosolutions (EBS).
Who are Retrophin's key executives?
Retrophin's management team includes the folowing people:
- Mr. Stephen J. Aselage, Chief Exec. Officer, Pres & Director (Age 67)
- Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 59)
- Mr. Neil F. McFarlane, Chief Operating Officer (Age 45)
- Ms. Elizabeth E. Reed, Sr. VP, Gen. Counsel & Corp. Sec. (Age 47)
- Dr. William E. Rote, Sr. VP of R&D (Age 55)
Has Retrophin been receiving favorable news coverage?
News coverage about RTRX stock has been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Retrophin earned a daily sentiment score of 0.13 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 41.45 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Retrophin's major shareholders?
Retrophin's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.19%), Millennium Management LLC (2.35%), Point72 Asset Management L.P. (2.33%), Dimensional Fund Advisors LP (2.32%), Northern Trust Corp (1.79%) and Oak Ridge Investments LLC (0.90%). Company insiders that own Retrophin stock include Alvin Shih, Elizabeth E Reed, Neil F Mcfarlane, Steve Aselage and William E Rote. View Institutional Ownership Trends for Retrophin.
Which institutional investors are selling Retrophin stock?
RTRX stock was sold by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, Spark Investment Management LLC, BlackRock Inc., Prudential Financial Inc., JPMorgan Chase & Co., Dynamic Technology Lab Private Ltd, Cubist Systematic Strategies LLC and BNP Paribas Arbitrage SA. Company insiders that have sold Retrophin company stock in the last year include Elizabeth E Reed, Neil F Mcfarlane and William E Rote. View Insider Buying and Selling for Retrophin.
Which institutional investors are buying Retrophin stock?
RTRX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Sphera Funds Management LTD., Point72 Asset Management L.P., A.R.T. Advisors LLC, UBS Group AG, Neuberger Berman Group LLC, Matarin Capital Management LLC and Dimensional Fund Advisors LP. View Insider Buying and Selling for Retrophin.
How do I buy shares of Retrophin?
Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Retrophin's stock price today?
One share of RTRX stock can currently be purchased for approximately $28.53.
How big of a company is Retrophin?
Retrophin has a market capitalization of $1.15 billion and generates $154.94 million in revenue each year. The biopharmaceutical company earns $-59,730,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Retrophin employs 173 workers across the globe.
How can I contact Retrophin?
Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]
MarketBeat Community Rating for Retrophin (RTRX)
MarketBeat's community ratings are surveys of what our community members think about Retrophin and other stocks. Vote "Outperform" if you believe RTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
